Part 2: Deregulated Expressions of PIWI Proteins and piRNAs as New Candidate Biomarkers and Potential Therapeutic Tools in Cancer by Meseure, Didier & Alsibai, Kinan Drak
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Provisional chapter
Part 2: Deregulated Expressions of PIWI Proteins and
piRNAs as New Candidate Biomarkers and Potential
Therapeutic Tools in Cancer
Didier Meseure and Kinan Drak Alsibai
Additional information is available at the end of the chapter
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
rt : r l t  r ssi s f I I r t i s  
iR s as e  Can i ate Bio arkers an  Potential 
Therapeutic Tools in Cancer
i i     i    l i i
dditional infor ation is available at the end of the chapter
Abstract
Epigenetic abnormalities are early events in carcinogenesis and associate heterogeneity 
of DNA methylation, modifications of histones, and deregulation of noncoding RNAs. 
Aberrant expressions of PIWI proteins and piRNAs were recently observed in numer-
ous subtypes of malignant tumors and were implicated in occurrence of most cancer 
hallmarks such as cell proliferation, genomic stability, apoptosis inhibition, invasion, and 
metastatic spread. However, this pathway is a new emerging research field, and further 
investigations are necessary to elucidate their oncogenic or tumor-suppressing status. 
Since the aberrant expression of this pathway may induce stemness, analysis of rela-
tionship between PIWI proteins, piRNAs, and cancer stem cells may open new avenues 
in cancer research. The objective of this review is to provide a broad overview of the 
emerging implication of PIWI proteins and piRNAs in carcinogenesis and their potential 
clinical interest as diagnostic and prognostic biomarkers and therapeutic tools.
Keywords: piRNA, PIWI proteins, transposable element (TE), transcriptional and 
post-transcriptional silencing, piRNA cluster, heterochromatin, DNA methylation, 
ping-pong cycle, Nuage
1. Deregulation of the PIWI-piRNA pathway in cancer
Recent evidences have suggested that activation of the PIWI-piRNA pathway has impor-
tant implications in carcinogenesis (Table 1). PIWI proteins and piRNAs are deregulated in 
numerous human cancers such as breast cancer, prostate cancer, hepatic cancer, gastric can-
cer, malignant melanoma, and lung cancer. Experimental analyses have demonstrated that 
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PIWI 
proteins
PiRNAs Cancer type Expression Cancer 
hallmarks
Mechanisms in 
cancer
References
PIWIL1 Breast cancer Overexpression Proliferation and 
stemness
Cell-cycle regulation [10]
PIWIL1 Lung cancer Overexpression CSC self-renewal Maintenance of CSCs [9]
PIWIL1 Ovary cancer Overexpression Migration and 
invasion
[72]
PIWIL1 Gastric cancer Overexpression Proliferation Cell-cycle regulation [8, 22, 62]
PIWIL1 Colon cancer Overexpression Proliferation and 
stemness
Interactions with 
OCT4 and SOX2
[17]
PIWIL1 Liver cancer Overexpression Proliferation [12]
PIWIL1 Cervix cancer Overexpression Migration and 
invasion
[5]
PIWIL1 Seminoma Overexpression Proliferation [21]
PIWIL1 Glioblastoma Overexpression Proliferation, 
migration, and 
invasion
Overexpression of 
MMP2 and MMP9
[11]
PIWIL1 Sarcomas Overexpression Genomic 
instability
Decreasing of 
differentiation and 
inhibition of TSGs 
(p15, p21, and p27)
[73]
PIWIL2 Colon cancer Overexpression Proliferation, 
migration, and 
invasion
MMP9 transcriptional 
activation
[14, 24]
PIWIL2 Breast cancer Overexpression Proliferation, 
apoptosis 
inhibition, 
migration, and 
invasion
Maintenance of 
CSCs, proliferation 
via STAT3/cyclin 
D1 activation, and 
apoptosis inhibition 
via STAT3/Bcl-xL 
activation
[16, 26] 
PIWIL2 Liver cancer Overexpression Apoptosis 
inhibition
PIWIL2/STAT3/ 
c-Src activation and 
repression of p53 
transcription
[12, 13]
PIWIL2 Cervix cancer Overexpression Apoptosis 
inhibition
PIWIL2/STAT3/ 
c-Src activation and 
repression of p53 
transcription
[29]
PIWIL2 Ovary cancer Overexpression Genomic 
instability
Chromatin 
decondensation, cell 
survival, and DNA 
repair
[65]
PIWIL4 Colon cancer Overexpression Migration and 
invasion
[74]
PIWIL4 Lung cancer Overexpression Proliferation Increasing of cyclin A 
and cdk2 expression
[68]
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PIWI proteins and piRNAs altered levels of expression are associated with major hallmarks 
of cancer, including genomic chronic proliferation, differentiation, and survival [1]. Emerging 
roles of PIWI-piRNA-mediated epigenetic alterations in cancer seem related to promotion of 
a stem-like state of tumor cells through aberrant DNA methylation. Experimental studies in 
Drosophila have confirmed that PIWI proteins and piRNAs functions are upstream modula-
tors of cell cycle progression and proliferation through control of DNA synthesis, maintain of 
chromatin structure, and assembly of mitotic spindle. In Drosophila, maternal alterations of the 
three PIWI proteins, Piwi, Aub, and Ago3, were associated with chromatin disorganization, 
asynchronous nuclear division, abnormal nuclear morphology, and cell cycle arrest. Analysis 
PIWI 
proteins
PiRNAs Cancer type Expression Cancer 
hallmarks
Mechanisms in 
cancer
References
PIWIL4 Cervix cancer Overexpression Proliferation, 
migration, and 
invasion
Impairing apoptosis 
via p14ARF/p53 
pathway
[34]
piR-651 Breast, colon, 
gastric, and lung 
cancers
Overexpression Proliferation, 
invasion, and 
metastasis
Cyclin D1 and CDK4 
overexpression
[28, 43, 69, 
70]
piR-932 Breast cancer Overexpression Stemness, EMT, 
and invasion
TGF-β pathway 
activation and 
hypermethylation of 
the TSG Latexin
[48]
piR-823 Gastric cancer Underexpression Chromatin 
regulation and 
angiogenesis
Hypomethylation 
via decreased 
DNMT3A/B and 
decreased pro-
angiogenic activity
[5]
piR-823 Multiple myeloma Overexpression DNA 
methylation and 
angiogenesis
Hypomethylation 
via decreased 
DNMT3A/B and 
decreased pro-
angiogenic activity
[44]
piR-
Hep1
Liver cancer Overexpression Migration and 
invasion
Akt phosphorylation 
and apoptosis 
inhibition via STAT3/
Bcl-xL pathway
[41, 71]
piR-
017061
Pancreatic cancer Underexpression [42]
piR-L-
163
Lung cancer Underexpression Proliferation and 
invasion
Cell-cycle regulation [38]
piR-
ABC
Bladder cancer Underexpression Inhibition of 
proliferation 
apoptosis 
promotion
TNFSF4 regulation [75]
Table 1. Role of PIWI and/or piRNA in carcinogenesis. This table shows recent evidences that deregulation (overexpression 
and/ or underexpression) of the PIWI-piRNA and PIWI proteins pathway in different cancer types has important 
implications in cancer hallmarks.
Part 2: Deregulated Expressions of PIWI Proteins and piRNAs as New Candidate Biomarkers… 3
of this pathway in cancer is still in its infancy, and investigation is currently underway to 
determine whether ectopic expression of piRNAs and PIWI proteins could have a driver role. 
Expression status and roles of the PIWI proteins and piRNAs remain poorly understood in 
cancer, and most of the current data about association of this pathway with carcinogenesis 
result from clinic-pathological reports. Aberrant expressions of these genes have been associ-
ated with various hallmarks of cancer and prognostic/predictive factors [2, 3].
1.1. Deregulation of PIWI proteins in cancer
Based mainly on both in vivo and in vitro functional studies combined with clinico-pathologic 
analysis, mounting evidence has identified all four human PIWI proteins as new molecular 
players in carcinogenesis [4]. Alterations of their expression levels are actually better inves-
tigated than piRNAs, with PIWI proteins overexpressed in germline and somatic malignant 
tumors. Deregulated PIWI proteins observed in somatic malignant tumors can be included in 
the cancer/testis antigens (CTAs) class and could thus be pertinent targets of immunotherapy 
[5]. They are linked to most of cancer hallmarks, suggesting an oncogenic role [6]. The four 
PIWI proteins PIWIL1/HIWI, PIWIL2/HILI, PIWIL3, and PIWIL4/HIWI2 were thus found to 
be involved in cancer cell proliferation, apoptosis, invasion, and metastasis and could repre-
sent diagnostic and prognostic biomarkers.
1.1.1. Proliferation, apoptosis, and stemness
PIWIL1: PIWIL1-induced DNA hypermethylation generates genetic and epigenetic changes 
promoting carcinogenesis [7]. PIWIL1 was upregulated in seminoma. In gastric cancer, 
PIWIL1 progressive increased expression was observed from preneoplastic lesions to inva-
sive cancer, whereas inhibition of PIWIL1 suppressed growth of tumor epithelial cells and 
induced cell-cycle arrest at the G2/M phase. PIWIL1 induced cyclin B1 overexpression and 
promoted cell cycle progression from G2 to M phase [8]. In sarcomas, PIWIL1 upregula-
tion was associated with repression of tumor differentiation and indefinite proliferation and 
inversely correlated with TSGs expression, including p15, p21, and p27. Lung cancer stem 
cells overexpressed PIWIL1 whose knockdown was associated with inhibition of sphere for-
mation ability and colony forming capacity in nude mice [9]. The promoting role of PIWIL1 in 
cell proliferation was also demonstrated in breast cancer [10]. In glioma, PIWIL1 repression 
was associated with inhibition of cell proliferation by promoting apoptosis and increasing 
cell cycle arrest. PIWIL1 induced cell cycle progression through increasing cyclin D1 and 
cyclin B levels of expression and repressed expression of p21, an inhibitor of cyclin D1 and 
CDK4, whereas its suppression through siRNAs blocked S phase entry via p21 upregula-
tion and cyclin D1 downregulation [11]. In hepatocellular carcinoma, PIWIL1 was underex-
pressed leading to reduction of proliferation and migration of cancer cells [12].
PIWIL2: PIWIL2-induced Stat3/Bcl-XL pathway activation promoted oncogenesis [13]. 
In breast cancer, PIWIL2 played an anti-apoptotic role and increased cancer stem cells 
proliferation by promoting the STAT3/Bcl-xL pathway [14]. PIWIL2 activated the STAT3/
cyclin D1 pathway. The splice isoform PL2L60 of PIWIL2 was overexpressed in tumors 
and was implicated in G0/1 to S phase transition and cancer cells proliferation through 
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activation of NF-κB and upregulation of STAT3 and Bcl-2 [15, 16]. In this way, PIWIL2 can 
directly bind to STAT3 protein via its PAZ domain and edify a PIWIL2/STAT3/c-Src triple 
protein-protein complex. Then, c-Src-induced phosphorylated STAT3 is translocated to the 
nucleus and binds to p53 promoter, inhibiting its transcription and reducing apoptosis in 
cancer cells. PIWIL2 silencing could reduce tumor proliferation and colony formation but 
increase apoptosis in vitro. PIWIL2 inactivation in colon cancer cells reduced proliferation 
and colony formation [14]. A significant positive correlation at mRNA level was observed 
between PIWIL1 and OCT4, as well as PIWIL2 and SOX2 in colon cancer cells [17]. In gastric 
cancer, PIWIL2 upregulated the expression of CDK2, CDK4, cyclin A, and c-Myc-dependent 
cyclin D1. In lung carcinoma, PIWIL2 enhanced CDK2 and cyclin A expression and initi-
ated mitotic phase [22]. In hepatocellular and cervical carcinoma, PIWIL2 promoted c-Myc 
expression through interaction of NME2 kinase to c-Myc promoter region [41]. PIWIL1 
and PIWIL2 modulated microtubules activity to increase malignant cell proliferation and 
invasion. PIWIL1 upregulated Stathmin1 expression, a pivotal cytosolic phosphoprotein 
implicated in edification of the mitotic spindle and segregation of chromosomes [43]. Direct 
interaction between Stathmin1 and PIWIL1 prevented its inhibition by CaMKII and its deg-
radation by E3 ubiquitin ligase RLIM. PIWIL2 promoted interaction of the tubulin folding 
cofactor B (TBCB) with HSP90 and repressed binding of TBCB to the E3 ubiquitin ligase 
adaptor protein gigaxonin, resulting in tubulin polymerization and microtubule edification 
during cell division [31].
PIWIL4: PIWIL4 also plays an oncogenic role in cervical cancer by inhibiting apoptosis 
through H3K9 methylation at the p14-ARF locus [18]. In glioma, PIWIL4 upregulated cyclin 
D1 expression and repressed the inhibitor of cyclin D1/CDK4 p16. PIWIL4 also promoted 
cyclin D1 expression through activation of STAT3, Bcl2, and Bcl-xL, and its expression was 
modulated by miR384 [46]. In cervical cancer, PIWIL4 promoted survival of cancer cells by 
inhibiting expression of p14-ARF and p53 and prevented apoptosis by inactivating the p14-
ARF/p53 axis. Furthermore, PIWIL4 downregulated PTEN expression and activity at the tran-
scriptional level, through DNMT1-induced hypermethylation of the PTEN gene promoter. 
PTEN inhibits numerous survival factors such as STAT3 and Akt/PI3K and through dephos-
phorylation induced by its phosphatase activity [1].
Furthermore, overexpression of PIWI proteins contributes to carcinogenesis by decreasing 
differentiation and promoting cancer stemness. PIWIL1 and PIWIL2 are implicated in main-
tenance and proliferation of lung and breast cancer stem cells, respectively [15].
1.1.2. Genomic integrity
Cancer cells overexpressing PIWI proteins often have genomic alterations partially resulting 
from reactivation of TEs. In sarcomas, PIWIL1, and p15, p21 and p27 expression levels are 
inversely correlated [7]. PIWI proteins maintain genome integrity in tumor cells by using 
epigenetic mechanisms. PIWIL1-induced carcinomas were characterized by global DNA 
hypermethylation at nonpromoter CpG regions. In mouse embryonic fibroblasts, PIWIL2 was 
implicated in DNA repair by promoting histone acetylation, chromatin relaxation, and DNA 
damage response [1].
Part 2: Deregulated Expressions of PIWI Proteins and piRNAs as New Candidate Biomarkers… 5
1.1.3. EMT, invasion, and metastasis
Reciprocal interactions between PIWI proteins and transcription factors involved in EMT 
have been identified [19]. In colon carcinomas, PIWI proteins and piRNA 34736 activate genes 
implicated in EMT [20].
The four PIWI proteins identified in humans are variably overexpressed in numerous can-
cers and implicated in invasion and metastatic spread. The first example of PIWI protein 
deregulated in carcinogenesis was that of PIWIL1 overexpression in seminomas [21]. Since 
then, increased levels of PIWIL1 have been detected in lung, breast, gastrointestinal tract, 
pancreas, liver, cervical, ovarian, and endometrial carcinomas. In most of these malignant 
tumors, PIWIL1 overexpression is associated with large tumor size, high histologic grade, 
advanced stage, and poorer prognosis [22–24]. Compared with PIWIL1 and PIWIL2, PIWIL3 
and PIWIL4 have been studied in few cancers.
PIWIL1 upregulation was implicated in carcinogenesis by promoting expression of CSC 
transcription factors OCT4, NANOG, and BMI1 with increased self-renewal properties and 
resistance to chemotherapies [25]. In breast cancer, PIWIL1 modified cell cycle progression 
through regulating levels of TGF-β receptors, CDK4, CDK6, and CDK8 [26]. During gastric 
carcinogenesis, PIWIL1 levels of expression were gradually increased in normal tissues, 
atrophic gastritis, intestinal metaplasia, and invasive carcinoma [25]. In colon cancer, PIWIL1 
overexpression induced global DNA methylation and proliferation. In hepatocellular carci-
nomas, PIWIL1 overexpression promoted invasion and metastatic spread, whereas PIWIL1 
inactivation decreased metastatic evolution [27]. In glioblastomas, PIWIL1 inactivation 
reduced migration by inactivating expression of MMP2 and MMP9 [1]. Conversely, PIWIL1 
had an inhibiting effect on invasion in ovarian cancer [28].
PIWIL2 upregulation was identified in various stages of cervical low-grade and high-grade 
squamous, intraepithelial lesions, and invasive cervical carcinomas and had the potential to 
be used as a complementary biomarker for p16 [29]. In colon cancer, PIWIL2 overexpres-
sion was significantly correlated with more aggressive clinical and pathological parameters, 
including lymph node and distant metastasis and poor prognosis [30]. PIWIL2 overexpres-
sion induced invasion through activation of MMP9, whereas PIWIL2 inhibition decreased 
migration via E-cadherin upregulation and TWIST, vimentin, and N-cadherin downregula-
tion [30]. Experimental PIWIL2 knockdown was associated with inhibition of colon cancer 
cells invasion through MMP9 downregulation. In breast cancer, PIWIL2 upregulation in can-
cer stem cells was correlated with large tumor size, high histological grade, estrogen receptor 
expression, proliferation marker Ki67, advanced tumor stage, and lymph node metastasis 
[26]. In prostate cancer, PIWIL2 overexpression was associated with deregulation of EMT 
factors. In breast cancer, PIWIL2 and piRNA 932 overexpression promoted EMT in CD44+/
CD24− CSCs [31].
PIWIL4 was upregulated in breast and renal cell cancers, as compared with normal tissue [32, 33]. 
PIWIL4 can also induce cervical cancer cell invasion through inhibiting p14/ARF and p53 
expression [34].
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1.2. Deregulation of piRNAs in cancer
Compared to PIWI proteins, few literatures are available about piRNAs in carcinogenesis. 
Despite numerous piRNAs are generated in the human genome, only a small number is 
consistently expressed in normal and tumor tissues [1]. With the previously established evi-
dence on PIWI proteins deregulation in cancer, the hypothesis that piRNAs are also aber-
rantly expressed in various cancers is very likely because piRNAs are pivotal part of the 
pi-RISC effector complexes that allow recognition of TEs. Deregulation of piRNAs that target 
mRNA transcripts containing TE-derived sequences could induce alterations of TSGs and 
oncogenes [15]. Deregulation of both PIWI proteins and molecules implicated in biogenesis 
of the PIWI-piRNA are also in favor of a driver role for piRNAs in cancer. Recent evidence 
suggests that piRNAs control transcriptional and post-transcriptional genes regulation in 
cancer cells through epigenetic mechanisms associating global DNA hypomethylation, gene-
specific DNA hypermethylation, and histones hypoacetylation, which result in oncogenes 
activation, TSG repression, genomic silencing, and induction of a stem-like state [35, 36]. 
Furthermore, piRNAs drive carcinogenesis by using nonepigenetic mechanisms such as 
cell cycle deregulation, proliferation, and invasion [37, 38]. Differential expressions of few 
piRNAs were reported between malignant tumors and normal tissues. Transcriptomic analy-
sis of 6260 human piRNAs from 11 types of tumors and normal tissues has revealed that 
among the 20,831 known piRNAs, only 522 piRNAs were expressed in tumor tissues in a 
cancer-type specific manner, whereas 273 piRNAs were expressed in normal tissues [39].
The first examples of piRNAs deregulated in cancer were piR-651, piR-823, and piR-932. PiR-651 
was aberrantly overexpressed in numerous tumors, such as breast, gastric, colon, and lung can-
cers, compared to normal tissues. By using small RNA sequencing techniques in breast cancer, 
over 100 deregulated piRNAs were identified in tumors compared to normal tissues, including 
piR-34736, piR-36249, piR-35407, piR-36318, piR-34377, piR-36743, piR-36026, and piR-31106. 
Among them, piR-36743, piR-36026, and piR-31106 were overexpressed, whereas piR-34736, 
piR-36249, piR-35407, piR-36318, and piR-34377 were underexpressed [33]. Furthermore, estro-
gen deficiency and the estrogen receptor ERβ controlled metastatic spread of breast cancer 
cells by directly modulating piRNA expression. Eight piRNAs were significantly differentially 
expressed between breast tumors and normal tissue, with overexpression of piR-4987, piR-
20365, piR-20485, and piR-20582 correlated with lymph node metastasis [33]. In lung cancer, 
555 piRNAs were differentially expressed between lung adenocarcinomas and squamous cell 
carcinomas and normal bronchial tissue. The most frequently underexpressed piRNA in lung 
cancer was piR-L-163, localized in intron 10 of the LAMC2 gene. PiR-651 promoted cyclin D1 
and CDK4 overexpression, resulting in G1 phase entry [38]. In gastric cancer, piR-823 underex-
pression and piR-651 overexpression were initially identified by using piRNA microarray and 
PCR compared to matched nonmalignant tissues. PiR-651 overexpression induced transition 
from G2 to M phase [40]. A total of 156 piRNAs, including piR-32105, piR-58099, and piR-59056, 
were significantly differentially expressed by using small RNA sequencing from a series of 
320 carcinomas and 38 nonmalignant tissues [1]. In liver cancer, piR-Hep1 was overexpressed 
compared to normal liver tissues. PiR-Hep1 levels of expression positively correlated with 
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PIWIL2, suggesting that piR-Hep1 may interact with PIWIL2 to induce carcinogenesis [41]. In 
pancreatic cancer, piR-017061, localized within HBII-296A snoRNA, was shown to be under-
expressed compared to normal pancreatic tissues [42]. In leukemias, piR-823 inhibited p16 
expression through activation of DNMT3A and DNMT3B, resulting in upregulation of cyclin 
D1 and CDK4. PiR_011186A downregulated p15 expression and thus promoted cyclin D1 and 
CDK4 upregulation through edification of a molecular complex combining DNMT1, EZH2, and 
Suv39H1 [44]. In kidney cancer, study of 24 tumors revealed that 19 piRNAs were differentially 
expressed between clear cell renal cell carcinomas and benign tissues. Furthermore, 46 piRNAs 
were differentially expressed between primary and metastatic carcinomas. Among piRNAs 
deregulated in renal cell metastatic carcinomas, three overexpressed piRNAs (piR-32051, piR-
39894, and piR-43607) were localized on the same piRNA cluster on chromosome 17 [43]. In 
multiple myeloma, piR-823 was significantly underexpressed in tumors, compared to normal 
tissues [44]. Furthermore, numerous PiRNAs, including piR-Hep1, piR-651, piR-823, piR-932, 
piR-L-163, piR-4987, piR-20365, piR-20485, piR-20582 and piR-ABC, were associated with hall-
marks of cancer and could be pertinent diagnostic and prognostic biomarkers [40, 41, 45].
1.2.1. Proliferation, survival, and apoptosis
In bladder cancer, piRNAs microarray study identified 106 overexpressed piRNAs and 91 
underexpressed piRNAs, including piRNA DQ594040. PiRABC repressed cancer cells pro-
liferation and increased cell apoptosis through TNFSF4 protein overexpression. In multiple 
myeloma, PiR-823 was upregulated and implicated in proliferation, apoptosis, cell-cycle regu-
lation, and angiogenesis related to DNMT3A and p16-INK4A repression and associated with 
advanced clinical stage [44]. PiRNA-823 repression promoted deregulation of cell cycle regula-
tors and apoptosis-related proteins and inhibited pro-angiogenic activity [44]. In glioblastoma, 
piR-598 promoted cancer cells survival and proliferation [46]. In lung carcinoma, piR-55490 
underexpression was associated with increased proliferation through reduction of piRNA-
induced 3’UTR mTOR mRNA binding and degradation. Furthermore, inhibition of piR-L-163 
enhanced DNA synthesis and promoted tumor cells survival and proliferation [38, 47].
1.2.2. Invasion and metastatic spread
In breast cancer, piR-4987 upregulation was significantly associated with lymph node metas-
tasis and PIWIL2-piR-932 complex enhanced EMT through Latexin methylation of its pro-
moter region [31, 48, 49]. In clear cell renal cell carcinoma, 19 piRNAs were differentially 
expressed between tumor and normal tissues and 46 piRNAs were associated with metastasis 
and poor survival [43]. PiRNA microarray analysis revealed 235 piRNAs upregulated and 
369 piRNAs downregulated in malignant tissue from 106 patient samples. RT-qPCR analysis 
confirmed that piR-57125 was downregulated in metastatic tumors, whereas piR-30924 and 
piR-38756 were upregulated [50]. In gastric cancer, downregulated blood levels of piR-823 
were correlated with stage, lymph node, and distant metastasis, suggesting that piRNAs 
may be pertinent blood biomarkers [51]. Furthermore, PiR-651 inhibition promoted growth 
suppression and cell cycle arrest at the G2/M stage [40]. In hepatocellular carcinoma (HCC), 
deep sequencing analysis identified oncogenic piR-Hep1 upregulation associated with 
PIWIL2 overexpression. Inhibition of piR-Hep1 repressed Akt phosphorylation, motility, and 
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invasion [41]. In pancreatic ductal adenocarcinoma, piR-017061 located within HBII-296A 
snoRNA was found to be downregulated in tumors compared to normal tissues [42]. In lung 
cancer, PiR-651 overexpression promoted survival, invasion, and metastatic progression 
through cyclin D1 and CDK4 overexpression [70]. In colon cancer, PiR-823 upregulation was 
correlated with lymph node and distant metastasis, whereas in gastric cancer, piR-823 over-
expression suppressed tumor cell growth [1, 69].
1.3. Mechanisms of the PIWI-piRNA pathway deregulation in cancer
Few studies have identified molecular mechanisms implicating PIWI proteins and piR-
NAs reactivation in carcinogenesis [52, 53]. The first hypothesis concerning deregulation 
of the PIWI-piRNA pathway in cancer results from its control of TEs propagation. In nor-
mal germline stem cells, piRNAs cooperate with abundant PIWI proteins to regulate TEs 
inactivation via DNA methylation. During embryonic development, these cells containing 
high levels of PIWI proteins develop into various somatic tissues in which PIWI proteins 
are not normally expressed. In cancer, recent studies have demonstrated that methylation 
of TEs was decreased, whereas TEs transcripts and proteins were upregulated and cor-
related with higher metastasis frequency [54, 55]. Prolonged exposure to detrimental envi-
ronmental factors may promote TEs mobilization with disruption of various TSGs via TEs 
Figure 1. The PIWI-piRNA pathway in germline and somatic cells, and mechanisms of the PIWI-piRNA pathway 
deregulation in cancer cells.
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integration [56]. A widespread hypomethylation of the genome during progression could 
induce both aberrant reactivation and propagation of TEs with reactive ectopic overex-
pression of the PIWI-piRNA pathway. High levels of piRNAs and PIWI proteins observed 
in somatic cancers could promote abnormal extensive DNA methylation, resulting in 
silencing of TSGs and acquisition of an aberrant stem-like state [57, 58]. The hypothesis 
that piRNAs guide PIWIL1 and PIWIL2 to transcriptionally silence TSGs is consolidated 
by analysis of their orthologs in mice, in which MILI and MIWI2 mutants fail to establish 
DNA methylation of TEs [59]. Furthermore, by suppressing expression of particular TEs, 
aberrant reactivation of the PIWI-piRNA axis in cancer may induce genomic and chro-
mosomal instability. Thus, this pathway could be implicated in cancer not only in repres-
sion of TEs but also in inactivation of various mRNAs not exposed to germline cells. The 
second hypothesis is the participation of this pathway in a putative biological system that 
can differentiate self from nonself RNA [60]. The third hypothesis is the ectopic and coor-
dinated reactivation and overexpression in cancer of cancer/testis antigens (CTA) normally 
restricted to the germline and including molecules of the PIWI-piRNA axis. As observed in 
normal gametogenesis, CTAs promote immortalization, implantation, and migration that 
could correspond in carcinogenesis to transformation, invasion, and metastasis, respec-
tively (Figure 1). In this ectopic context, reactivation of the PIWI-piRNA pathway could 
confer properties of proliferative germline stem cells to cancer cells [61–68].
2. PIWIs and piRNAs as potential biomarkers and therapeutic tools
2.1. PIWI proteins as biomarkers
PIWIL1 overexpression was correlated with poor 5-year survival in malignant glioma, hepa-
tocellular, gastric cancer, colon cancer, pancreatic ductal adenocarcinoma, and ovarian cancer 
[1]. In hepatocarcinoma, PIWIL1 high levels of expression were correlated with larger tumor 
size, intrahepatic metastasis, overall survival, and recurrence-free survival [41]. PIWIL2 
upregulation was observed in breast cancer, colon cancer, gastrointestinal stromal tumors, 
renal cell carcinoma, and endometrial carcinoma. In colorectal cancer, PIWIL2 overexpression 
was associated with aggressive clinico-pathological characteristics and poorer prognostic [30]. 
In esophageal cancer, PIWIL2 was significantly correlated to high histological grade, advanced 
clinical stage, and poorer clinical outcomes. Furthermore, PIWIL2 upregulation was identified 
in a cancer cell subpopulation expressing OCT4 and NANOG stemness factors, suggesting a 
role in stem-cell maintenance and self-renewal. In breast cancer, PIWIL2 was mainly located in 
cancer stem cells and showed different expression patterns, with slight nuclear localization in 
preneoplastic lesions and cytoplasmic/nucleus topography in invasive and metastatic cancers. 
Its upregulation was correlated with poorer survival [33]. PIWIL2 can promote invasion and 
metastasis among various cancers by increasing c-Myc expression through binding of NM/
NM23 nucleoside diphosphate kinase 2 (NME2) to G4-motif region within c-Myc. In hepa-
tocellular carcinoma, nuclear co-expression of PIWIL2 and PIWIL4 had a worse prognostic 
phenotype [71]. In ovarian cancer, PIWIL2 overexpression was associated with cisplatin resis-
tance and poorer prognostic [28]. PIWIL3 and PIWIL4 overexpression were associated with 
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worse prognosis in breast cancer. In gastric cancer, PIWIL1-4 upregulation was significantly 
associated with TNM stage histological grade and lymph node metastasis [15, 40, 62].
2.2. PiRNAS as biomarkers
PiRNAs are increasingly investigated as diagnostic and prognostic biomarkers [69]. PiRNAs 
are small RNAs of only 24–32 nt in length which can pass through cell membrane. Like miR-
NAs, piRNAs are not degraded in circulation and possess the capability to resist incubation 
and storage conditions used in laboratories. They are thus detectable in patient samples like 
blood plasma and serum, saliva, sputum, and urine. Furthermore, piRNAs possess higher 
sensitivity and specificity compared to an existing lncRNA and miRNA-based biomarkers. 
They are highly expressed in germinal tissues, but also although at lower levels in various 
somatic normal tissues, saliva, and plasma-derived exosomes. Furthermore, piRNAs present 
higher specificity and sensitivity, when compared to miRNAs. In breast cancer, 8 piRNAs 
were identified as independent prognostic markers and associated with overall survival [63]. 
Moreover, piR-4987 upregulation in peripheral blood was correlated with lymph node metas-
tasis [48]. In gastric cancer, piR-651 high level of expression in peripheral blood was associated 
with poor differentiation, advanced TNM stage, and metastasis. A three-piRNA signature, 
including piR-59056, piR-54878, and piR-62701, could separate patients by risk of recurrence 
[5]. PiR-651 was also upregulated in other cancers, including lung, colon, and breast tumors. 
In clear cell renal cell carcinoma, piR-30924 and piR-57125 were shown to be independent 
prognostic predictors in nonmetastatic patients. In colon cancer, piR59056, piR-54878, and 
piR-62701 were associated with recurrence-free survival. Few studies have investigated on 
interactions between piRNAs and PIWI proteins in cancer [70, 72–75]. Actually, it remains 
unclear whether PIWI proteins independently possess cytoplasmic pro-oncogenic properties 
that promote cancer cell proliferation, invasion, and metastasis or PIWI proteins located in the 
nucleus epigenetically modulate numerous biological processes by edifying ribonucleoproteic 
complexes with piRNAs.
2.3. PIWI proteins and piRNAs as therapeutic tools
Recent studies have revealed the potential for piRNAs as therapeutic tools that target 
PIWI proteins and oncoproteins [71]. Mounting evidence has revealed that upregulation 
of PIWI proteins was negatively correlated with patient survival, and that downregula-
tion of PIWI proteins could reduce the number of G2/M phase cells and enhance expres-
sion of p53 protein, thus inhibiting proliferation and promoting apoptosis. In addition, 
PIWI proteins could increase resistance to chemotherapy drugs such as cisplatin, and 
their downregulation could increase sensitivity of cancer cells to cisplatin. In this way, 
synthetic piRNAs targeting PIWI genes are potential pertinent tools in transcriptional 
silencing during cancer progression, and PIWI antibodies targeting PIWI proteins con-
stitute another approach to antagonize cancer cells proliferation at post-transcriptional 
level. Synthetic piRNAs could also block synthesis of cancer-related proteins by bind-
ing to mRNAs. Compared to miRNAs, piRNAs do not require enzymes processing and 
have better specificity to targets. In a mouse model, artificial piRNAs could be obtained 
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through expression of sense and antisense transcripts, resulting in epigenetic silencing of 
target genes [1, 72]. Furthermore, piRNAs could be considered as tools to regulate expres-
sion levels of TSGs. A lncRNA (GAS5)/SnoRNA-derived piRNA enhanced activation of 
TRAIL gene by site-specifically recruiting MLL/COMPASS-like complexes with induction 
of H3K4 methylation and H3K27 demethylation, resulting in transcriptional activation of 
TRAIL and inhibition of tumor growth [64].
3. Conclusion and perspectives
PiRNAs and PIWI proteins were first recognized more than a decade ago and are coming into 
attention with development of high-throughput sequencing technologies and bioinformat-
ics methods. This pathway is considered as a conserved immune-like surveillance process to 
suppress propagation of TEs in germline cells and various types of somatic mostly nonaging 
cells. Furthermore, the PIWI-piRNA pathway seems to be implicated in maintain of the genome 
organization, epigenetic modifications of genes expression, and identification of self and non-
self genes that are trans-generationally inherited. Moreover, this axis could be implicated in 
dual DNA/RNA-level regulation of genes expression. Nevertheless, there is still lack of com-
plete understanding of the functions and interactions of piRNAs and PIWI proteins. Therefore, 
the complicated biogenesis and functions of piRNAs need further elucidation to improve our 
understanding of the implication of these molecules in cancer. Since discovery of the unexpected 
role of this pathway in seminoma, aberrant levels of expression of these molecules have been 
observed across numerous malignant tumors, though further research is needed to elucidate 
their oncogenic or tumor-suppressing status. Growing evidence suggests that the PIWI-piRNA 
pathway modulates occurrence of most of cancer hallmarks. PIWI proteins and piRNAs could be 
pertinent diagnostic/prognostic biomarkers in cancer and therapeutic tools in targeted therapies. 
However, the potential driver role of a deregulated PIWI-piRNA pathway in cancer needs to 
be further evaluated. Furthermore, it remains unclear whether PIWI proteins regulate cancer 
cell proliferation, apoptosis, metastasis, and invasion in the cytoplasm independently or PIWI 
proteins perform epigenetic control of homeostasis by taken to the nucleus with piRNAs. Most 
importantly, since the aberrant expression of this pathway may induce stemness, analysis of 
relationship between PIWI proteins, piRNAs, and cancer stem cells may open new avenues in 
future investigations.
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